Research pinpoints West Nile virus antibody binding site

August 14, 2006

West Lafayette, Ind. -- Researchers have learned the precise location where an antibody binds to the West Nile virus, and they have suggested a mechanism for how this antibody neutralizes the virus to prevent infection.

"Science doesn't yet fully understand exactly how neutralizing antibodies work," said Michael Rossmann, the Hanley Distinguished Professor of Biological Sciences in Purdue's College of Science. "This work has shown precisely where the antibody binds to the virus, and we now have a theory for how it interacts with the virus to disarm it. Perhaps we are starting to understand why this particular antibody can inhibit the infectivity of the virus, which is important to understand if a vaccine is going to be developed."

Purdue worked with researchers from the Washington University School of Medicine in St. Louis.

West Nile belongs to a family of viruses known as flaviviruses, which includes a number of dangerous insect-borne disease-causing viruses. The antibody attaches to a protein called an E protein, for envelope protein, which makes up the virus's outer shell. There are 180 copies of E proteins symmetrically arranged in 60 sets of three, forming a geometric shape called an icosahedron, which is made up of triangular facets.

The researchers, however, were surprised to discover that this antibody recognizes only two of the E proteins in each set of three, said Bärbel Kaufmann, a postdoctoral research associate working in the Rossmann lab.

"This finding was very unusual," she said. "If the E proteins really are the same, why doesn't the antibody bind to all of the E proteins? This kind of asymmetry, where you have two proteins binding and one not binding, has not been seen before."

The researchers theorize that, although chemically identical, these E proteins exist in different environments relative to each other and might, therefore, have slightly different structures, said Richard J. Kuhn, a professor and head of Purdue's Department of Biological Sciences.

The findings were detailed in a research paper appearing last week in Proceedings of the National Academy of Sciences.

Researchers know that when the virus infects a host cell, it interacts with the cell membrane in such a way that it is swallowed up by the membrane and enters the cell as an "endocytotic particle." The Purdue researchers have now developed a theory for the mechanism behind the interaction and will test it in further research, Rossmann said.

Once the virus penetrates the host cell, the viral membrane fuses with an internal membrane in the cell. This process causes the virus particle to empty its contents inside the cell and leads to infection.

To study how the antibodies and E proteins attach, Kaufmann first separated the antibody's tail end from its two grasping, fingerlike structures called "antigen binding fragments."

"We don't want to handle the whole molecule, so we cut off these antigen binding domains and then combined them with the virus, forming the virus-antibody complex," Kaufmann said.

The researchers then used an electron microscope and a process called cryoelectron microscopy to take detailed pictures of this complex. Then they computed a three-dimensional model based on these pictures showing the outstretched antigen binding fragments attached to the virus particle.

The E proteins in one triangular segment of the icosahedron are not all positioned the same way relative to each other and to the various "axes" that define the icosahedron. This difference in position appears to be crucial in the binding process.

The antibody is called a monoclonal antibody because it recognizes only a single binding site on the E protein. Each E protein has three "domains," or well-defined, folded segments. The third domain has a structure commonly seen in molecules that attach to proteins to perform a specific function in cells. The grasping antibody segment used in the study attaches only to the third domain of the E proteins.

"One of the three E proteins in the triangular segment fails to be recognized by the antibody because its third domain crowds together with other E proteins on the viral surface," Kuhn said.

Researchers at the Washington University School of Medicine have shown through experiments that the antibody does not prevent the virus from attaching to human cells, so it is likely that the antibody works by preventing the fusion step from occurring.

Purdue researchers had previously theorized that before the virus fuses, the E protein undergoes dramatic structural repositioning and that the antibodies might inhibit those changes, preventing infection.

"We have a model for understanding how this inhibition process may work," Rossmann said. "We think it's likely that the antibody blocks the positional changes needed for the E protein before fusion, in effect preventing the virus from infecting the cell by jamming the mechanism."

After infection, it takes a few days to a few weeks for the body to make the antibodies, or enough of them to fend off infection.

"If the virus is fast enough, you become sick," Kuhn said. "But if you were vaccinated, you might already have enough antibodies to prevent infection, and that's why these findings are ultimately important. If we understand the mechanism of neutralization, then we might be able to design more effective vaccines."

West Nile virus causes a potentially fatal illness and has infected thousands of people in the United States over the past five years, killing more than 700 people in that time frame.

The research is funded by the National Institutes of Health. Future work could focus on confirming the theoretical model for the antibody's neutralizing mechanism.

"If our theory is right and the antibody binding blocks the E protein's transformation so that fusion can't take place, then we should be able to capture the intermediate stages of this rearrangement of the E protein prior to fusion," Kaufmann said.
-end-
The paper was authored by Kaufmann, Purdue electron microscopist Paul R. Chipman, Purdue associate research scientist Wei Zhang, Kuhn and Rossmann, and three researchers from the Washington University School of Medicine: Grant E. Nybakken, a graduate student in the Department of Pathology and Immunology; Michael S. Diamond, an assistant professor in the departments of Medicine, Molecular Microbiology, Pathology and Immunology; and Daved H. Fremont, an associate professor of pathology and immunology, biochemistry and molecular physics.

Writer: Emil Venere, (765) 494-4709, venere@purdue.edu

Sources: Michael Rossmann, (765) 494-4911, mgr@indiana.bio.purdue.edu

Richard J. Kuhn, (765) 494-1164, kuhnr@purdue.edu

Barbel Kaufmann, bkaufman@bilbo.bio.purdue.edu

Related Web sites:

Michael Rossmann: http://www.biology.purdue.edu/people/faculty/rossmann/index.htm

Richard Kuhn: http://www.biology.purdue.edu/people/faculty/kuhn/index.htm

A publication-quality image is available at http://news.uns.purdue.edu/images/+2006/rossmann-westnile.jpg

Purdue University

Related Antibodies Articles from Brightsurf:

Scientist develops new way to test for COVID-19 antibodies
New research details how a cell-free test rapidly detects COVID-19 neutralizing antibodies and could aid in vaccine testing and drug discovery efforts.

Mussels connect antibodies to treat cancer
POSTECH research team develops innovative local anticancer immunotherapy technology using mussel protein.

For an effective COVID vaccine, look beyond antibodies to T-cells
Most vaccine developers are aiming solely for a robust antibody response against the SARS-CoV-2 virus, despite evidence that antibodies are not the body's primary protective response to infection by coronaviruses, says Marc Hellerstein of UC Berkeley.

Children can have COVID-19 antibodies and virus in their system simultaneously
With many questions remaining around how children spread COVID-19, Children's National Hospital researchers set out to improve the understanding of how long it takes pediatric patients with the virus to clear it from their systems, and at what point they start to make antibodies that work against the coronavirus.

The behavior of therapeutic antibodies in immunotherapy
Since the late 1990s, immunotherapy has been the frontline treatment against lymphomas where synthetic antibodies are used to stop the proliferation of cancerous white blood cells.

Re-engineering antibodies for COVID-19
Catholic University of America researcher uses 'in silico' analysis to fast-track passive immunity

Seroprevalence of antibodies to SARS-CoV-2 in 10 US sites
This study estimates how common SARS-CoV-2 antibodies are in convenience samples from 10 geographic sites in the United States.

Neutralizing antibodies in the battle against COVID-19
An important line of defense against SARS-CoV-2 is the formation of neutralizing antibodies.

Three new studies identify neutralizing antibodies against SARS-CoV-2
A trio of papers describes several newly discovered human antibodies that target the SARS-CoV-2 virus, isolated from survivors of SARS-CoV-2 and SARS-CoV infection.

More effective human antibodies possible with chicken cells
Antibodies for potential use as medicines can be made rapidly in chicken cells grown in laboratories.

Read More: Antibodies News and Antibodies Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.